Abstract
Only a few breast cancer histologic subtypes harbor distinct genetic alterations that
are associated with a specific morphology (genotype-phenotype correlation). Secretory
carcinomas and adenoid cystic carcinomas are each characterized by recurrent translocations,
and invasive lobular carcinomas frequently have CDH1 mutations. Solid papillary carcinoma with reverse polarity is a rare breast cancer
subtype with a distinctive morphology and recently identified IDH2 mutations. We review the clinical and pathologic features and underlying genetic
alterations of those breast cancer subtypes with established genotype-phenotype correlations
and discuss the phenotypes associated with germline mutations in genes associated
with hereditary breast cancer.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Surgical Pathology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors.Mod Pathol. 2014; 27: S80-S97
- WHO classification of tumours of soft tissue and bone. IARC, Lyon (France)2013
- WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon (France)2008
- WHO classification of tumours of the breast. IARC, Lyon (France)2012
- Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.Cancer Cell. 2002; 2: 367-376
- Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.Proc Natl Acad Sci U S A. 2009; 106: 18740-18744
- Comprehensive molecular portraits of invasive lobular breast cancer.Cell. 2015; 163: 506-519
- IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity.Cancer Res. 2016; 76: 7118-7129
- Basal-like breast cancer and the BRCA1 phenotype.Oncogene. 2006; 25: 5846-5853
- Phenotype-genotype correlation in familial breast cancer.J Mammary Gland Biol Neoplasia. 2011; 16: 27-40
- Breast carcinoma in children.JAMA. 1966; 195: 388-390
- Secretory carcinoma of the breast.Cancer. 1980; 45: 2404-2413
- Secretory carcinoma of the breast: results from the survival, epidemiology and end results database.Breast. 2012; 21: 350-353
- Rare breast cancers: 246 invasive secretory carcinomas from the national cancer data base.J Surg Oncol. 2016; 113: 721-725
- Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature.World J Surg Oncol. 2005; 3: 35
- Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature.Mod Pathol. 2012; 25: 567-575
- Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum.Mod Pathol. 2009; 22: 291-298
- Secretory carcinoma of the breast and its histopathological mimics: value of markers for differential diagnosis.Histopathology. 2013; 63: 509-519
- Rare breast carcinomas: adenoid cystic carcinoma, neuroendocrine carcinoma, secretory carcinoma, carcinoma with osteoclast-like giant cells, lipid-rich carcinoma, and glycogen-rich clear cell carcinoma.in: Dabbs D.J. Breast pathology. Elsevier Saunders, Philadelphia2012: 573-595
- Cystic hypersecretory (in situ) carcinoma of the breast: a clinicopathologic and immunohistochemical characterization of 10 cases with clinical follow-up.Am J Surg Pathol. 2014; 38: 45-53
- The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.Cancer Res. 2001; 61: 8909-8916
- Mammary analogue secretory carcinoma of salivary glands containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.Am J Surg Pathol. 2010; 34: 599-608
- Mammary analogue secretory carcinoma.Arch Pathol Lab Med. 2016; 140: 997-1001
- Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion.Am J Surg Pathol. 2015; 39: 601-610
- Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by RT-PCR: report of 4 cases harboring ETV6-X gene fusion.Am J Surg Pathol. 2016; 40: 3-13
- Update from the 4th edition of the World Health Organization classification of head and neck tumours: tumors of the salivary gland.Head Neck Pathol. 2017; 11: 55-67
- Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.Mod Pathol. 2017; 30: 1086-1099
- Secretory breast carcinoma: a histopathologic and genomic spectrum characterized by a joint specific ETV6-NTRK3 gene fusion.Am J Surg Pathol. 2015; 39: 1458-1467
- What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).Ann Oncol. 2016; 27: 920-926
Available at: https://clinicaltrials.gov/. Accessed June 27, 2017.
- Adenoid cystic carcinoma of the breast.Hum Pathol. 1987; 18: 1276-1281
- Adenoid cystic carcinoma of the breast: value of histologic grading and proliferative activity.Am J Surg Pathol. 1998; 22: 569-575
- Adenoid cystic carcinoma of the breast: a histologic, cytologic, and immunohistochemical study.Semin Diagn Pathol. 1989; 6: 153-164
- Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome.Cancer. 2002; 94: 2119-2127
- Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers.Mod Pathol. 2006; 19: 1351-1357
- Genomic landscape of adenoid cystic carcinoma of the breast.J Pathol. 2015; 237: 179-189
- MYB is essential for mammary tumorigenesis.Cancer Res. 2011; 71: 7029-7037
- Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.Mod Pathol. 2016; 29: 1292-1305
- Recurrent fusions in MYB and MYBL1 define a common, transcription factor-driven oncogenic pathway in salivary gland adenoid cystic carcinoma.Cancer Discov. 2016; 6: 176-187
- MYB, MYBL1, MYBL2, and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma.Histopathology. 2017; 71: 823-834
- MYB labeling by immunohistochemistry is more sensitive and specific for breast adenoid cystic carcinoma than MYB labeling by FISH.Am J Surg Pathol. 2017; 41: 973-979
- MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features.Hum Pathol. 2014; 45: 2270-2280
- Rare breast cancer: 933 adenoid cystic carcinomas from the national cancer data base.Ann Surg Oncol. 2013; 20: 2236-2241
- Adenoid cystic carcinoma of the breast, 20 years of experience in a single center with review of the literature.Breast Cancer. 2017; ([Epub ahead of print])
- Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials.Head Neck. 2016; 38: 620-627
- Morphologic mimics of invasive lobular carcinoma.Arch Pathol Lab Med. 2015; 139: 1253-1257
- Cadherin-catenin complex dissociation in lobular neoplasia of the breast.Breast Cancer Res Treat. 2012; 132: 641-652
- Invasive lobular carcinoma of the breast: morphology, biomarkers and ‘omics.Breast Cancer Res. 2015; 17: 12
- E-cadherin immunohistochemistry in breast pathology: uses and pitfalls.Histopathology. 2016; 68: 57-69
- The cell-cell adhesion molecule e-cadherin.Cell Mol Life Sci. 2008; 65: 3756-3788
- E-cadherin germline mutation in familial gastric cancer.Nature. 1998; 392: 402-405
- Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond.JAMA Oncol. 2015; 1: 23-32
- CDH1 mutations and hereditary lobular breast cancer.Fam Cancer. 2016; 15: 215-219
- Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.J Med Genet. 2015; 52: 361-374
- Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: report of 5 cases.Am J Surg Pathol. 2003; 27: 1114-1118
- Breast tumor resembling tall cell variant of papillary thyroid carcinoma.Am J Clin Pathol. 2017; 147: 399-410
- Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms: a unique invasive tumor with indolent behavior.Am J Surg Pathol. 2017; 41: 887-895
- Breast carcinomas with an unexpected inside out growth pattern. Rotation of polarization associated with angioinvasion.Pathol Res Pract. 1993; 189 ([abstract]): 780
- Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma.Pathol Res Pract. 1994; 190: 668-674
- Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein.Mod Pathol. 2004; 17: 1045-1050
- Molecular pathways: isocitrate dehydrogenase mutations in cancer.Clin Cancer Res. 2016; 22: 1837-1842
- IDH mutations in cancer and progress toward development of targeted therapeutics.Ann Oncol. 2016; 27: 599-608
- Molecular portraits of human breast tumours.Nature. 2000; 406: 747-752
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA. 2001; 98: 10869-10874
- Defining breast cancer intrinsic subtypes by quantitative receptor expression.Oncologist. 2015; 5: 474-482
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.Mod Pathol. 2006; 19: 264-271
- Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.Mod Pathol. 2011; 24: 157-167
- Histologic types of breast cancer: how special are they?.Mol Oncol. 2010; 4: 192-208
- BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.Am J Surg Pathol. 2007; 31: 121-128
- Rare breast cancer subtypes: histological, molecular and clinical peculiarities.Oncologist. 2014; 19: 805-813
- A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.J Med Genet. 2010; 47: 771-774
Article info
Publication history
Published online: December 14, 2017
Footnotes
The authors have no financial disclosures.
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
